STAT3 and osteosarcoma: Indeed, osteosarcoma is a highly aggressive malignancy with very limited pharmacological therapeutic options, and the activation of the STAT3 pathway is associated with tumor progression, cell survival, drug resistance, and adverse prognosis in this malignancy [108,109].